| Patient | Ray Charles |
|---|---|
| Date of birth | 1960-09-23 |
| Identifiers | MRN HR-ML009-SYN; SSN (made up) 000-09-5561 |
| Document date | 2026-03-03 |
| Author | Gloria Fenwick, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
The patient attends this visit for establishing primary care: accessible care for a blind adult, recovery-oriented review, and depression and safety screening. [S]
Hemoglobin: 14.2 g/dL; Sodium: 139 mmol/L; Potassium: 4.2 mmol/L; Creatinine: 0.98 mg/dL; eGFR: 84 mL/min/1.73 m²; Glucose: 94 mg/dL; Calcium: 9.4 mg/dL; Total cholesterol: 186 mg/dL; HDL cholesterol: 54 mg/dL; LDL cholesterol: 110 mg/dL; Triglycerides: 110 mg/dL; HbA1c: 5.5%; PHQ-9: 2; AUDIT-C: 2; DAST-10: 0. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-03 | Body height | 178 | cm | S |
| 2026-03-03 | Body weight | 80 | kg | S |
| 2026-03-03 | Body mass index (BMI) [Ratio] | 25.2 | kg/m2 | S |
| 2026-03-03 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-03-03 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-03-03 | Heart rate | 68 | /min | S |
| 2026-03-03 | Respiratory rate | 14 | /min | S |
| 2026-03-03 | Body temperature | 36.7 | Cel | S |
| 2026-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-03 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-03-03 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-03 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-03 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-03 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-03 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-03 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-03-03 | Cholesterol [Mass/volume] in Serum or Plasma | 186 | mg/dL | <=200 mg/dL | Normal | S |
| 2026-03-03 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-03-03 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 110 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-03-03 | Triglyceride [Mass/volume] in Serum or Plasma | 110 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-03-03 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| 2026-03-03 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 2026-03-03 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 2026-03-03 | Total score [DAST-10] | 0 | {score} | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils | One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response, and call 911 | Nasal route | 2026-03-03 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Blindness of both eyes since childhood, no light perception; cause never diagnosed | active | confirmed | H54.0X55 | S — Synthetic modern coding of the documented childhood blindness; category 5 (no light perception) is a synthetic grading of what the sources call blindness. |
| Opioid use disorder (heroin), in sustained remission for more than thirty years, without medication treatment | active | confirmed | F11.21 | S — Synthetic modern coding of the publicly admitted heroin addiction and his documented recovery; listed as an active problem because it is managed at every visit, with remission carried by the code. |